ALNY - Alnylam Pharmaceuticals, Inc.
78.59 0.00 (0.00%)
After hours: 4:51PM EDT
| Previous Close | 81.26 |
| Open | 80.95 |
| Bid | 76.37 x 2900 |
| Ask | 96.00 x 1400 |
| Day's Range | 78.29 - 81.68 |
| 52 Week Range | 78.29 - 153.99 |
| Volume | 617,592 |
| Avg. Volume | 926,252 |
| Market Cap | 7.911B |
| Beta (3Y Monthly) | 3.25 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.87 |
| Earnings Date | Nov 5, 2018 - Nov 9, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 139.82 |
- ACCESSWIRE•3 hours ago
IMPORTANT SHAREHOLDER NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 18, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Alnylam Pharmaceuticals, Inc. ("Alnylam" or "the Company") (NASDAQ: ALNY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between February 15, 2018 and September 12, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before November 26, 2018.
- GlobeNewswire•6 hours ago
CLASS ACTION UPDATE for PZZA, ALNY and CHGG: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, Oct. 18, 2018 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..
- ACCESSWIRE•22 hours ago
ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. - ALNY
NEW YORK, NY / ACCESSWIRE / October 17, 2018 / Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ...
- GlobeNewswire•yesterday
SHAREHOLDER ALERT: TRCO MCHP ALNY MGTI CPB CHGG ADNT TRVN SFIX: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, Oct. 17, 2018 -- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a.
- ACCESSWIRE•yesterday
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alnylam Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ALNY
NEW YORK, NY / ACCESSWIRE / October 17, 2018 / Pomerantz LLP announces that a class action lawsuit has been filed against Alnylam Pharmaceuticals, Inc. (''Alnylam'' or the ''Company'') (ALNY) and certain of its officers. The class action, filed in United States District Court, Southern District of New York, and index under 18-cv-08845, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise acquired Alnylam securities between February 22, 2017 and July 19, 2018, both dates inclusive (the ''Class Period''), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the ''Exchange Act'') and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Market Realist•yesterdayHow Acadia Pharmaceuticals Is Positioned Financially
Wall Street analysts anticipate that Acadia Pharmaceuticals (ACAD) will generate revenues of $56.07 million in the third quarter of 2018, representing a ~57.59% YoY (year-over-year) growth. Its net revenues grew ~87% to $57.06 million in the second quarter, from $30.5 million in the second quarter of 2017.
Market Realist•yesterdayAnalysts Mostly Positive on Acadia Pharmaceuticals
Wall Street analysts anticipate that Acadia Pharmaceuticals (ACAD) will report net income of -$63.01 million for the third quarter of 2018. It was -$63.3 million in the second quarter, which compares to -$67.4 million in the second quarter of 2017. In the first half of this year, its net income was -$117.66 million. In the first half of 2017, it was -$155.3 million.
- ACCESSWIRE•2 days ago
IMPORTANT SHAREHOLDER DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 16, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Alnylam Pharmaceuticals, Inc. ("Alnylam" or "the Company") (NASDAQ: ALNY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between February 15, 2018 and September 12, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before November 26, 2018.
- Zacks•2 days ago
Alnylam to Pursue Full Approval & Rolling NDA for Givosiran
Alnylam (ALNY) plans to pursue a full approval of givosiran and submit rolling new drug application (NDA) for the same.
- GlobeNewswire•2 days ago
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CBS, PVG, COCP and ALNY
NEW YORK, Oct. 16, 2018 -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a.
Market Realist•2 days agoGauging Analysts’ Views of Sarepta Stock in October
Of the 23 analysts covering Sarepta Therapeutics (SRPT) in October, eight analysts gave the stock a “strong buy” rating, 14 analysts gave it a “buy” rating, and one analyst gave Sarepta Therapeutics a “hold” rating.
- ACCESSWIRE•3 days ago
IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 15, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Alnylam Pharmaceuticals, Inc. ("Alnylam" or "the Company") (NASDAQ: ALNY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between February 15, 2018 and September 12, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before November 26, 2018.
- GlobeNewswire•3 days ago
CLASS ACTION UPDATE for COCP, ABBV and ALNY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, Oct. 15, 2018 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..
- ACCESSWIRE•3 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alnylam Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ALNY
NEW YORK, NY / ACCESSWIRE / October 15, 2018 / Pomerantz LLP announces that a class action lawsuit has been filed against Alnylam Pharmaceuticals,Inc. ("Alnylam" or the "Company") (ALNY) and certain of its officers. The class action, filed in United States District Court, Southern District of New York, and index under 18-cv-08845, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise acquired Alnylam securities between February 22, 2017 and July 19, 2018, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Market Realist•3 days agoA Look at Sarepta Therapeutics’ Stock Performance
Sarepta Therapeutics (SRPT) has a sponsored research and exclusive license option agreement with Genethon for advancing the latter’s microdystrophin gene therapy program. Sarepta also has a sponsored research and exclusive license option agreement with Duke University for advancing its gene-editing CRISPR/Cas9 technology for muscular dystrophy. Sarepta had submitted a marketing authorization application (or MAA) for eteplirsen to the European Medicines Agency (or EMA) in November 2016.
- GlobeNewswire•3 days ago
Kessler Topaz Meltzer & Check, LLP - Important Deadline Reminder for Alnylam Pharmaceuticals, Inc. Investors
Important Deadline Reminder: Investors who purchased Alnylam securities during the Class Period may, no later than November 26, 2018, seek to be appointed as a lead plaintiff representative of the class.
Market Realist•3 days agoKey Collaborations Bode Well for Sarepta Therapeutics
Sarepta Therapeutics (SRPT) is working with several strategic partners for developing multiple treatment approaches to DMD. These partners include Nationwide Children’s Hospital, Myonexus, Genethon, Duke University, and Summit Limited.
- MarketWatch•3 days ago
Alnylam shares drop 1.8% on new FDA approval strategy for rare disease drug
Alnylam Pharmaceuticals Inc. shares dropped 1.8% in Monday premarket trade after the company announced that it intends to apply for full U.S. approval of its rare disease drug, rather than a faster-than-usual approval, signifying a more extended approval timeline for the therapy. The drug, givosiran, is currently in a phase 3 clinical trial, with preliminary results expected in early 2019. Alnylam plans to submit a "rolling" new drug application with the Food and Drug Administration starting this year, with full clinical trial results from the phase 3 trial to be submitted in mid-2019. Givosiran is intended for acute hepatic porphyria, a group of rare genetic diseases characterized by attacks that can be life-threatening, as well as chronic and painful symptoms. Alnylam's decision to go for full approval is "not a surprise to us: this plan is, in our opinion, a byproduct of faster than expected enrollment of the phase III Envision trial, and we'd be buying the stock on any weakness that ensues," said Stifel analyst Paul Matteis, who noted that company management had previously suggested that this might happen. Alnylam shares have dropped 23.8% over the last three months, compared with a 1.2% decline in the S&P 500 and a 1.3% rise in the Dow Jones Industrial Average .
Market Realist•3 days agoAnalyzing Sarepta’s Product Pipeline
Sarepta Therapeutics’ (SRPT) Exondys 51 uses exon-skipping technology to skip exon 51 of the DMD gene. The drug is designed to bind to exon 51, which leads to an exclusion or skipping of this exon during mRNA processing. Golodirsen uses exon-skipping technology to skip exon 53 of the DMD gene.
- Business Wire•3 days ago
Alnylam Announces Plan to Initiate Rolling Submission of a New Drug Application and Pursue Full Approval for Givosiran
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, today announced that in consultation with the U.S. Food and Drug Administration (FDA), the Company plans to pursue a full approval based on the complete results of the ENVISION Phase 3 study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) for the treatment of acute hepatic porphyria (AHP), rather than filing based on the interim Phase 3 results. The FDA has also agreed to a rolling submission of a New Drug Application (NDA), which will be initiated in 2018 with full clinical sections submitted in mid-2019, assuming positive study results.
- ACCESSWIRE•6 days ago
IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 12, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Alnylam Pharmaceuticals, Inc. ("Alnylam" or "the Company") (NASDAQ: ALNY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between February 15, 2018 and September 12, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before November 26, 2018.
- GlobeNewswire•6 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alnylam Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – ALNY
NEW YORK, Oct. 12, 2018 -- Pomerantz LLP announces that a class action lawsuit has been filed against Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY).
Market Realist•6 days agoUnderstanding Sarepta Therapeutics’ Operational Performance
Sarepta Therapeutics’ (SRPT) cost of sales increased from $506,000 in the second quarter of 2017 to $6.73 million in the second quarter. Sarepta’s cost of sales primarily consists of inventory costs, overhead costs, and royalty payments to BioMarin Pharmaceutical (BMRN). These royalty payments resulted from the settlement and licenses agreements in July 2017. Sarepta Therapeutics’ gross income increased from $34.48 million in the second quarter of 2017 to $66.8 million in the second quarter.
- GlobeNewswire•6 days ago
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of NVRO, LOGM, USAT, ABBV and ALNY
NEW YORK, Oct. 12, 2018 -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a.
- GlobeNewswire•6 days ago
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alnylam Pharmaceuticals, Inc. (ALNY) and Lead Plaintiff Deadline – November 26, 2018
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (ALNY) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Alnylam securities between February 15, 2018 through September 12, 2018, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/alny. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. A class action lawsuit has already been filed.
